About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker GERN · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Aug 26, 2026A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetels…
NCT05371964 · Myelofibrosis
Imetelstat sodium, Ruxolitinib
GERN
Geron Corporation
Phase 1Active, not recruiting30Feb 2027Registry ↗
Jul 17, 2026Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System…
NCT02598661 · Myelodysplastic Syndromes
Imetelstat Sodium, Placebo
GERN
Geron Corporation
Phase 2/3Active, not recruiting289Oct 13, 2023Registry ↗
Jul 8, 2026A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or H…
NCT04576156 · Myelofibrosis
Imetelstat, Best Available Therapy (BAT)
GERN
Geron Corporation
Phase 3Active, not recruiting327Jun 30, 2028Registry ↗
Jun 17, 2026Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treate…
NCT01242930 · Multiple Myeloma
Imetelstat (7.5 mg/kg), lenalidomide standard of care
GERN
Geron Corporation
Phase 2Completed13Nov 2014Registry ↗
Jun 24, 2024Expanded Access for Treatment With Imetelstat
NCT05937568 · Myelodysplastic Syndromes
Imetelstat
GERN
Geron Corporation
—Approved for marketing——Registry ↗
Sep 21, 2021Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
NCT01731951 · Primary Myelofibrosis, Secondary Myelofibrosis
Imetelstat
GERN
Geron Corporation
Phase 2Completed80May 24, 2018Registry ↗
Sep 14, 2021Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or Hi…
NCT02426086 · Myelofibrosis
Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg
GERN
Geron Corporation
Phase 2Completed107Apr 26, 2018Registry ↗
Jan 26, 2016Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Re…
NCT01256762 · Locally Recurrent or Metastatic Breast Cancer
Imetelstat sodium, Bevacizumab
GERN
Geron Corporation
Phase 2Completed166Oct 2012Registry ↗
Jan 26, 2016Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia…
NCT01243073 · Essential Thrombocythemia, Polycythemia Vera
Imetelstat
GERN
Geron Corporation
Phase 2Completed20Oct 2013Registry ↗
Jan 26, 2016Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cance…
NCT01137968 · Non-small Cell Lung Cancer
imetelstat, Bevacizumab
GERN
Geron Corporation
Phase 2Completed116Sep 2013Registry ↗
Dec 24, 2015A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Meta…
NCT00732056 · Breast Cancer
GRN163L
GERN
Geron Corporation
Phase 1Completed24Sep 2011Registry ↗
Dec 24, 2015Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
NCT00718601 · Multiple Myeloma
Imetelstat Sodium (GRN163L)
GERN
Geron Corporation
Phase 1Completed40Oct 2011Registry ↗
Dec 24, 2015Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multipl…
NCT00594126 · Multiple Myeloma
Imetelstat Sodium (GRN163L)
GERN
Geron Corporation
Phase 1Completed20Jul 2011Registry ↗
Dec 24, 2015Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small…
NCT00510445 · Lung Cancer
Imetelstat Sodium (GRN163L)
GERN
Geron Corporation
Phase 1Completed27Apr 2011Registry ↗
Dec 24, 2015Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor M…
NCT00310895 · Solid Tumor Malignancies
Imetelstat Sodium (GRN163L)
GERN
Geron Corporation
Phase 1Completed85Mar 2013Registry ↗
Dec 24, 2015Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
NCT00124189 · Chronic Lymphoproliferative Diseases
GRN163L
GERN
Geron Corporation
Phase 1Completed48Mar 2013Registry ↗

16 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:44 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances